Al-Sawaf O et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 4-year follow-up analysis of the randomized CLL14 study. EHA 2021;Abstract S146
Barr PM et al. Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. ASCO 2021;Abstract 7523
Bishop M et al. Second-line tisagenlecleucel or standard care in aggressive b-cell lymphoma. N Engl J Med 2021 Feb 17;386(7):629-39.Abstract
Budde LE et al. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: Phase I dose-escalation study. J Clin Oncol 2022;40(5):481-91.Abstract
Byrd J et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: Results of the first randomized phase III trial. J Clin Oncol 2021 Nov 1;39(31):3441-52.Abstract
Caimi PF et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): A multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2021;22(6):790-800.Abstract
Dickinson M et al. Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results. ASCO 2022;Abstract 7500
Duell J et al. Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica 2021;106(9):2417-26.Abstract
Falchi L et al. Subcutaneous epcoritamab with rituximab + lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial. ASCO 2022;Abstract 7524
Ghia P et al. Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study. ASCO 2021;Abstract 7501
Hillmen P et al. First interim analysis of alpine study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. EHA 2021;Abstract LB1900
Hutchings M et al. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. J Clin Oncol 2021;39(18):1959-70.Abstract
Jacobson C et al. Long-term survival and gradual recovery of B-cells in patients with refractory large b-cell lymphoma treated with axicabtagene ciloleucel (Axi-Cel). Blood 2021;136(1 suppl);40-42.Abstract
Jacobson C et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet 2022;23(1):91-103.Abstract
Jain P et al. Ibrutinib with rituximab in first-line treatment of older patients with mantle cell lymphoma. J Clin Oncol 2022;40(2):202-12.Abstract
Kahl B et al. Tailoring upfront therapy in mantle cell lymphoma. SOHO 2021;Abstract S186
Kamdar M et al. Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) t cell therapy, versus standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (Pts) with relapsed or refractory (R/R) large b-cell lymphoma (LBCL): Results from the randomized phase 3 Transform study. ASH 2021;Abstract 91
Kater A et al. Fixed-duration ibrutinib and venetoclax (i+v) versus chlorambucil plus obinutuzumab (CLB+O) for first-line (1L) chronic lymphocytic leukemia (CLL): Primary analysis of the phase 3 GLOW study. EHA 2021;Abstract LB1902
Locke FL et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 2022;386(7):640-54.Abstract
Locke FL et al. Primary analysis of ZUMA‑7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard‑of‑care therapy in patients with relapsed/refractory large b-cell lymphoma. ASH 2021;Abstract 2
Ma S et al. Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy. Blood 2021;138(10):836-46.Abstract
Mato AR et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): A phase 1/2 study. Lancet 2021;397(10277):892-901.Abstract
Mato AR et al. Pirtobrutinib, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: Updated results from the phase 1/2 BRUIN study. ASH 2021;Abstract 391
Matasar MJ et al. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2021;22(5):678-89.Abstract
Morschhauser F et al. Glofitamab as monotherapy and in combination with Obinutuzumab induces high complete response rates in patients with multiple relapsed or refractory (R/R) follicular lymphoma (FL). ASH 2021;Abstract 128
Munir T et al. First prospective data on minimal residual disease (MRD) outcomes after fixed-duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of CLL in elderly or unfit patients: The Glow study. ASH 2021;Abstract 70
Neelapu S et al. Axicabtagene ciloleucel as first-line therapy in high-risk large b-cell lymphoma: The phase 2 ZUMA-12 trial. Nature Medicine 2022;28:735-42.Abstract
Palomba ML et al. Safety and preliminary efficacy in patients with relapsed/refractory mantle cell lymphoma receiving lisocabtagene maraleucel in TRANSCEND NHL 001. Blood 2020;136(Suppl 1):10-11.Abstract
Sharman J et al. Acalabrutinib ± obinutuzumab vs obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: ELEVATE-TN 4-year follow-up. EHA 2021;Abstract S148
Sehn LH et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: Survival update and new extension cohort data. Blood Adv 2022;6(2):533-43.Abstract
Seymour JF et al. Characterization of bruton tyrosine kinase inhibitor (BTKi)-related adverse events in a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia (CLL). ASH 2021;Abstract 3721
Schuster SJ. Bispecific antibodies for the treatment of lymphomas: Promises and challenges. Hematol Oncol 2021;39(Suppl 1):113-16.Abstract
Tam CS et al. SEQUOIA: Results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). ASH 2021;Abstract 396
Tam CS et al. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv 2021;5(12):2577-85.Abstract
Tilly H et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 2022;386(4):351-63.Abstract
Trask P et al. Obinutuzumab short duration infusion is preferred by healthcare providers and has minimal impact on patient-reported symptoms among patients with untreated, advanced follicular lymphoma. ASH 2021;Abstract 1345
Wang M et al. Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL). ASCO 2022;Abstract LBA7502
Wang M et al. Outcomes with KTE-X19 in patients with relapsed/refractory mantle cell lymphoma in ZUMA-2 who had progression of disease within 24 months of diagnosis. EHA 2021;Abstract EP787
Wang M et al. Pirtobrutinib, a next generation, highly selective, non-covalent BTK inhibitor in previously treated mantle cell lymphoma: Updated results from the phase 1/2 BRUIN study. ASH 2021;Abstract 381
Wierda WG et al. Transcend CLL 004: Phase 1 cohort of lisocabtagene maraleucel (liso-cel) in combination with ibrutinib for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). ASH 2020;Abstract 544